TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00541606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist collaboration in diabetes care
Description: Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.
Study: NCT01299753

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: identically packed placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: 20-40 mg q6-8h
Study: NCT04132440

Intervention type: OTHER
Intervention: Interview
Description: Complete interview

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT02768272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PCEA vs PIEB
Description: We evaluate the relation between the distribution of L-bupivacaine plus fentanyl in the epidural space and the incedence of breaktrough pain during labor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epidural vs CSE
Description: We evaluate the relation between the type of epidural technique and the incedence of breaktrough pain during labor
Study: NCT01153750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glivec
Study: NCT01838200

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) vaccine
Description: BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) vaccine
Description: BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) vaccine
Description: BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG) vaccine
Description: BCG was to be administered as a single intralesional injection (200 µL volume) on Day 1 at varying doses depending on cohort assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab was to be administered as a 90-minute IV infusion at a dose of 3 mg/kg every 3 weeks (± 3 days) on Days 36, 57, 78, and 99.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid
Description: Isoniazid was to be administered orally at a dose of 300 mg (3 × 100 mg tablets) every day from Days 29 through 56.
Study: NCT01740570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.~Phase II: Maximum tolerated dose from Phase I.
Study: NCT02834871

Intervention type: DEVICE
Group type: OTHER
Intervention: Electromyogram

Intervention type: DEVICE
Group type: OTHER
Intervention: Electromyogram
Study: NCT02188758

Intervention type: OTHER
Intervention: Adults - CFPE Treatment
Description: Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
Study: NCT01819493

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Family-based group lifestyle intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Family-Based intervention
Description: Comparison intervention
Study: NCT05918159

Intervention type: OTHER
Intervention: Sarcopenia Assessment
Description: The prevalence of sarcopenia in a group of elderly people and its correlation with other health variables was determined.
Study: NCT00036933

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MUC-2-Globo H-KLH conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QS21
Study: NCT00696280

Intervention type: BEHAVIORAL
Intervention: Functional Living Index - Emesis
Study: NCT03959995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT)
Description: Ambulatory, consistently supervised group exercise training (3 training sessions of 40-45 min/week each). 10-12-week blocks of non-linearly periodized high intensity resistance and high impact aerobic dance exercises (HIT-setting) intermitted by 4-6-week periods of endurance-type exercise with high volume and lower intensity. Indi-vidualized training schedules for the RT-section.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Wellness
Description: control group: 3x 10 week blocks, 1 training session/week à 45 min; stretching, light functional gymnastics, yoga with less strengthening techniques over 13 months.
Study: NCT03214302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Disoproxil Fumarate
Description: Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
Study: NCT02384291

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alpha-Bio GRAFT Natural Bovine Bone
Description: Pure Hydroxyapatite ceramic mineral with high similarity to the human bone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: natural bone substitute
Description: natural bone substitute material derived from the mineral portion of bovine bone
Study: NCT01631682

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: 40mg single pill

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reactivation
Description: subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: 1800mg, 9 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Description: 32 IU, 8 self-administered intranasal sprays, 4 in each nostril
Study: NCT02874404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K-delta Inhibitor TGR-1202
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K-delta Inhibitor TGR-1202
Description: Given PO
Study: NCT00319852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-IPV combined vaccine
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP vaccine
Description: 0.5 mL, IM
Study: NCT03435172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device-ADRCs intravenously infusion
Description: Medical Device: ADRCs Generated by Celution 800 IV Device and then Infused into Peripheral Vein.
Study: NCT04766567

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean section with cesarean myomectomy (serosal)
Description: Serosal or endometrial myomectomy performed during cesarean section

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cesarean section with cesarean myomectomy (serosal)
Description: Serosal or endometrial myomectomy performed during cesarean section

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cesarean section without myomectomy
Description: Cesarean delivery without performing myoemctomy
Study: NCT01332812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control group
Description: General anesthesia, without additional interventions
Study: NCT04379934

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 3-hydroxybuturate
Description: 3-hydroxybuturate will be administered directly as a modified Krebs Henseleit buffer in a super perfused atrial strips model

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: 3-hydroxybuturate
Description: 3-hydroxybuturate will be administered directly as a modified Krebs Henseleit buffer in a super perfused atrial strips model
Study: NCT05323682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized physical exercise program
Description: An individualized physical exercise program was programmed, monitored remotely by e-mail or the use of an activity wristband

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NO Individualized physical exercise program
Description: Usual medication
Study: NCT03807557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Constraint-induced movement therapy
Description: i.Robotic repetitive task-specific training followed by task-oriented practice: during each session, participants first receive 60 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 30 minutes of functional practice using shaping technique.~ii.Restraint of the unaffected limb: Patients will wear a mitt to restrict the unaffected hand during training at clinic for 0.5 hours of functional practice each session, 3 sessions per week for 8 weeks.~iii. Transfer package: The transfer package aims at transferring the therapy gains to the participant's real world by use of a set of behavioral techniques. This is intended to have the participant responsible for adhering to the treatment requirements and encourage active engagement in the functional practice outside of the clinic setting. The participants will be given appropriated home assignment practicing daily activities outside of the clinic.
Study: NCT00937768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01600183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UNFO-s
Description: The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cast
Description: casting of the infant legs
Study: NCT03807557

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional UE rehabilitation training
Description: focusing on UE training and including neuro-developmental techniques(Bobath, 1990), trunk-arm control (ie, practice UE tasks during standing), weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
Study: NCT03657017

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET/MR
Description: Performed on a hybrid PET/MR scanner before treatment start (N = 150). Among those patients, 10 patients are examined with PET/MR in the completion of neoadjuvant chemotherapy and a follow-up scan three months after the completion of radiotherapy.
Study: NCT01155648

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chest wall compression for ten minutes in chest
Study: NCT00039442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given orally
Study: NCT00921076

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait Analysis
Description: A computerized motion analysis system to observe the effect of ankle arthroplasty versus ankle arthrodesis on the kinematic behaviour of the foot and ankle during gait.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gait Analysis
Description: A computerized motion analysis system to observe the effect of ankle arthroplasty versus ankle arthrodesis on the kinematic behaviour of the foot and ankle during gait.
Study: NCT00440973

Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: monoclonal antibody with anti-angiogenesis properties used as chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Interleukin-2
Description: immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T \& B lymphocyte proliferation
Study: NCT00039442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02744755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab - GP2017
Description: Adalimumab - GP2017

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab - US licensed Humira
Description: Adalimumab - US licensed Humira
Study: NCT01606553

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-intensity IMT
Description: High intensity short duration respiratory muscle training with a valve prototype

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham High-intensity IMT
Description: High intensity short duration respiratory muscle training using a sham valve prototype
Study: NCT02285634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxymetazoline 0.05%
Description: sterile gauze soaked in 5 milliliters (mL) of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine 0.25%
Description: sterile gauze soaked in 5 milliliters (mL) of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 1% plus epinephrine 1:100,000
Description: sterile gauze soaked in 5 milliliters (mL) of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
Study: NCT02787694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Factor Targeted Walking Training
Description: Individuals walk on a treadmill for 30 minutes while exposed to either endurance, balance, challenge, strength, or speed focused approaches

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: treadmill
Study: NCT02285634

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic 0.9% NaCL
Description: sterile gauze soaked in 5 milliliters (mL) of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
Study: NCT03601624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 1. Pomalidomide at 4 mg orally on days 1-21 of a 28 day cycle~2. Cyclophosphamide 300 mg IV on days 1 and 15 of a 28 day cycle.~3. Dexamethasone 40 mg PO weekly.(Or 20 mg if patients are older than 75 years )
Study: NCT00607295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clino-san vaginal lubricant
Description: Clino-san 2ml vaginal application 3 times per week for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clino-san vaginal lubricant
Description: Clino-san 2ml vaginal application 3 times per week for 12 weeks
Study: NCT03572842

Intervention type: OTHER
Group type: OTHER
Intervention: quantiferon monitor test
Description: different blood test with quantiferon monitor
Study: NCT01396382

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTATATE PET scan
Description: 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography (PET). Efficacy of the 68Ga-DOTATATE PET scan was assessed and compared to 111In-Pentetreotide scan and to scans with CT and/or MRI. Safety and toxicity were also assessed with pre-injection and post-imaging vital signs, pulse oximetry on room air, 12 lead ECGs, and blood laboratory tests, including tumor markers, liver and renal functions and blood counts, and direct patient questioning. Late delayed tumor markers, liver and renal functions and blood counts were assessed when available.
Study: NCT00699530

Intervention type: OTHER
Intervention: Cabergoline
Description: Cabergoline 0,25 - 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.
Study: NCT01883492

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femoral Stem
Description: JMDN classification/Class III device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Stem
Description: JMDN classification/Class III device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acetabular Cup
Description: JMDN classification: Class III device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acetabular Cup
Description: JMDN classification: Class III device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acetabular Liner
Description: JMDN classification: Class III device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acetabular Liner
Description: JMDN classification: Class III device
Study: NCT00796068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo single or double unit UCBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Undergo single or double unit UCBT
Study: NCT03721432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 150mg
Description: pregabalin 150 mg capsules (Lyrica®,Pfizer) given 60 minutes prior to epidural anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule given 60 minutes prior to epidural anesthesia
Study: NCT00817635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCI699
Description: LCI699 oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LCI699-matching Placebo
Description: LCI699-matching placebo oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Eplerenone-matching Placebo
Description: Eplerenone-matching placebo oral capsules
Study: NCT04002973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00037
Description: Noninvasive regional oximeter.
Study: NCT03862833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL2
Description: Three IL2 levels will be tested:~Level 1: 2 millions UI/Infusion Level 2: 4 millions UI/Infusion Level 3: 6 millions UI/Infusion 4 weeks, 5 days per week from day + 15 post graft to day + 40

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: 4 mg at day +15 post graft
Study: NCT00456274

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Frequent baseline blood sampling
Description: 3 ml of blood sampled every 10 minutes for a total of 8-12 hours